MDGL logo

Madrigal Pharmaceuticals (MDGL) Cash From Financing

Annual CFF

$595.12 M
+$281.67 M+89.86%

December 31, 2023


Summary


Performance

MDGL Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMDGLcash flowmetrics:

Quarterly CFF

$7.46 M
-$126.66 M-94.44%

September 30, 2024


Summary


Performance

MDGL Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMDGLcash flowmetrics:

TTM CFF

$1.20 B
-$12.12 M-1.00%

September 30, 2024


Summary


Performance

MDGL TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMDGLcash flowmetrics:

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

MDGL Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+89.9%-94.4%-1.0%
3 y3 years+10000.0%-94.4%-1.0%
5 y5 years+89.3%-94.4%-1.0%

MDGL Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+247.5%-98.7%-100.0%-1.0%+1641.8%
5 y5-yearat high>+9999.0%-98.7%-100.0%-1.0%>+9999.0%
alltimeall timeat high>+9999.0%-98.7%+121.2%-1.0%+4524.9%

Madrigal Pharmaceuticals Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$7.46 M(-94.4%)
$1.20 B(-1.0%)
Jun 2024
-
$134.12 M(-76.6%)
$1.21 B(+8.2%)
Mar 2024
-
$573.71 M(+19.5%)
$1.12 B(+87.5%)
Dec 2023
$595.12 M(+89.9%)
$479.92 M(+2351.1%)
$595.12 M(+56.8%)
Sep 2023
-
$19.58 M(-54.4%)
$379.54 M(+5.4%)
Jun 2023
-
$42.93 M(-18.5%)
$359.96 M(-1.7%)
Mar 2023
-
$52.69 M(-80.1%)
$366.14 M(+16.8%)
Dec 2022
$313.45 M(+83.1%)
$264.34 M(>+9900.0%)
$313.45 M(+356.8%)
Sep 2022
-
$0.00(-100.0%)
$68.62 M(-23.5%)
Jun 2022
-
$49.11 M(>+9900.0%)
$89.72 M(-13.9%)
Mar 2022
-
$0.00(-100.0%)
$104.14 M(-39.2%)
Dec 2021
$171.24 M(+3265.5%)
$19.50 M(-7.6%)
$171.24 M(+9.5%)
Sep 2021
-
$21.10 M(-66.8%)
$156.36 M(+15.3%)
Jun 2021
-
$63.54 M(-5.3%)
$135.61 M(+87.9%)
Mar 2021
-
$67.09 M(+1349.4%)
$72.18 M(+1318.7%)
Dec 2020
$5.09 M(+2065.1%)
$4.63 M(+1222.6%)
$5.09 M(+1008.5%)
Sep 2020
-
$350.00 K(+221.1%)
$459.00 K(+218.8%)
Jun 2020
-
$109.00 K(>+9900.0%)
$144.00 K(-5.3%)
Mar 2020
-
$0.00(0.0%)
$152.00 K(-35.3%)
Dec 2019
$235.00 K(-99.9%)
$0.00(-100.0%)
$235.00 K(-72.2%)
Sep 2019
-
$35.00 K(-70.1%)
$845.00 K(-33.0%)
Jun 2019
-
$117.00 K(+41.0%)
$1.26 M(-99.6%)
Mar 2019
-
$83.00 K(-86.4%)
$314.15 M(-0.1%)
Dec 2018
$314.33 M(+80.9%)
$610.00 K(+35.3%)
$314.33 M(-30.0%)
Sep 2018
-
$451.00 K(-99.9%)
$449.25 M(+0.1%)
Jun 2018
-
$313.01 M(>+9900.0%)
$448.80 M(+163.0%)
Mar 2018
-
$265.00 K(-99.8%)
$170.67 M(-1.8%)
Dec 2017
$173.81 M(+1102.5%)
$135.53 M(>+9900.0%)
$173.81 M(+292.9%)
Sep 2017
-
$0.00(-100.0%)
$44.23 M(-3.5%)
Jun 2017
-
$34.88 M(+926.2%)
$45.86 M(+168.1%)
Mar 2017
-
$3.40 M(-42.9%)
$17.10 M(+18.3%)
Dec 2016
$14.45 M(+338.0%)
$5.95 M(+266.4%)
$14.45 M(+46.7%)
Sep 2016
-
$1.63 M(-73.5%)
$9.85 M(-136.5%)
Jun 2016
-
$6.13 M(+716.7%)
-$27.01 M(-524.6%)
Mar 2016
-
$750.00 K(-44.4%)
$6.36 M(+92.8%)
Dec 2015
$3.30 M
$1.35 M(-103.8%)
$3.30 M(-1019.2%)
Sep 2015
-
-$35.24 M(-189.2%)
-$359.00 K(-100.6%)
Jun 2015
-
$39.50 M(-1809.1%)
$60.69 M(-19.5%)
DateAnnualQuarterlyTTM
Mar 2015
-
-$2.31 M(+0.1%)
$75.37 M(-11.6%)
Dec 2014
$85.30 M(+23.5%)
-$2.31 M(-108.9%)
$85.30 M(-41.0%)
Sep 2014
-
$25.82 M(-52.3%)
$144.46 M(+22.0%)
Jun 2014
-
$54.17 M(+611.2%)
$118.43 M(+84.0%)
Mar 2014
-
$7.62 M(-86.6%)
$64.38 M(-6.8%)
Dec 2013
$69.04 M(-40.2%)
$56.85 M(<-9900.0%)
$69.04 M(-1.7%)
Sep 2013
-
-$211.00 K(-275.8%)
$70.26 M(-25.6%)
Jun 2013
-
$120.00 K(-99.0%)
$94.42 M(-0.3%)
Mar 2013
-
$12.28 M(-78.9%)
$94.75 M(-18.0%)
Dec 2012
$115.52 M(+214.4%)
$58.07 M(+142.5%)
$115.52 M(+101.3%)
Sep 2012
-
$23.95 M(+5331.1%)
$57.37 M(+72.4%)
Jun 2012
-
$441.00 K(-98.7%)
$33.29 M(-50.8%)
Mar 2012
-
$33.05 M(<-9900.0%)
$67.68 M(+84.2%)
Dec 2011
$36.74 M(-18.6%)
-$69.00 K(-48.9%)
$36.74 M(-12.3%)
Sep 2011
-
-$135.00 K(-100.4%)
$41.90 M(-25.2%)
Jun 2011
-
$34.84 M(+1556.5%)
$55.99 M(+167.8%)
Mar 2011
-
$2.10 M(-58.7%)
$20.91 M(-53.7%)
Dec 2010
$45.16 M(-2221.0%)
$5.10 M(-63.5%)
$45.16 M(+13.8%)
Sep 2010
-
$13.96 M(-5750.2%)
$39.68 M(+57.3%)
Jun 2010
-
-$247.00 K(-100.9%)
$25.22 M(+1.4%)
Mar 2010
-
$26.35 M(-6980.2%)
$24.87 M(-1268.2%)
Dec 2009
-$2.13 M(+11.7%)
-$383.00 K(-24.2%)
-$2.13 M(-11.3%)
Sep 2009
-
-$505.00 K(-14.6%)
-$2.40 M(-7.7%)
Jun 2009
-
-$591.00 K(-9.1%)
-$2.60 M(+13.0%)
Mar 2009
-
-$650.00 K(-0.5%)
-$2.30 M(+20.7%)
Dec 2008
-$1.91 M(-104.3%)
-$653.00 K(-7.2%)
-$1.91 M(+25.2%)
Sep 2008
-
-$704.00 K(+140.3%)
-$1.52 M(+62.1%)
Jun 2008
-
-$293.00 K(+14.5%)
-$939.00 K(-14.5%)
Mar 2008
-
-$256.00 K(-4.8%)
-$1.10 M(-102.5%)
Dec 2007
$43.88 M(+11.7%)
-$269.00 K(+122.3%)
$43.88 M(-0.6%)
Sep 2007
-
-$121.00 K(-73.2%)
$44.15 M(-0.3%)
Jun 2007
-
-$452.00 K(-101.0%)
$44.27 M(-1.0%)
Mar 2007
-
$44.73 M(-6667.5%)
$44.73 M(-6667.5%)
Dec 2006
$39.29 M(+939.7%)
-
-
Dec 2005
$3.78 M(-95.5%)
-
-
Mar 2005
-
-$681.00 K
-$681.00 K
Dec 2004
$84.28 M(+18.5%)
-
-
Dec 2003
$71.12 M
-
-

FAQ

  • What is Madrigal Pharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for Madrigal Pharmaceuticals?
  • What is Madrigal Pharmaceuticals annual CFF year-on-year change?
  • What is Madrigal Pharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Madrigal Pharmaceuticals?
  • What is Madrigal Pharmaceuticals quarterly CFF year-on-year change?
  • What is Madrigal Pharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Madrigal Pharmaceuticals?
  • What is Madrigal Pharmaceuticals TTM CFF year-on-year change?

What is Madrigal Pharmaceuticals annual cash flow from financing activities?

The current annual CFF of MDGL is $595.12 M

What is the all time high annual CFF for Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals all-time high annual cash flow from financing activities is $595.12 M

What is Madrigal Pharmaceuticals annual CFF year-on-year change?

Over the past year, MDGL annual cash flow from financing activities has changed by +$281.67 M (+89.86%)

What is Madrigal Pharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of MDGL is $7.46 M

What is the all time high quarterly CFF for Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals all-time high quarterly cash flow from financing activities is $573.71 M

What is Madrigal Pharmaceuticals quarterly CFF year-on-year change?

Over the past year, MDGL quarterly cash flow from financing activities has changed by -$126.66 M (-94.44%)

What is Madrigal Pharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of MDGL is $1.20 B

What is the all time high TTM CFF for Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals all-time high TTM cash flow from financing activities is $1.21 B

What is Madrigal Pharmaceuticals TTM CFF year-on-year change?

Over the past year, MDGL TTM cash flow from financing activities has changed by -$12.12 M (-1.00%)